Efficacy of Ultomiris Pediatric TMA Treatment

By João L. Carapinha

June 18, 2025

In this update we detail the results of the ALXN1210-TMA-314 Phase III trial. It shows that Ultomiris pediatric TMA treatment achieved an overall survival rate of 87% at 26 weeks in pediatric patients with thrombotic microangiopathy (TMA) followin...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.